Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to Their Actions: Part II

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2010 Jun 2

PMID 20514211

Citations 14

Authors

R Miller

Affiliations

Soon will be listed here.

Abstract

Rapid-onset psychotic rebound is uncommon on discontinuation of most antipsychotic drugs, as might be expected for antipsychotic drugs with (hypothetically) indirect actions at their final target receptors. Rapid-onset psychosis is more common on withdrawal of clozapine, which might be expected if its action is direct. Drugs other than clozapine (notably thioridazine) may have hitherto unrecognised similarities to clozapine (but without danger of agranulocytosis), and may be useful in treatment of refractory psychosis. Quetiapine fulfils only some criteria for a clozapine-like drug. Clinical response to neuroleptics varies widely at any given plasma level. Haase's "neuroleptic threshold" concept suggests that the dose producing the slightest motor side effects produces most or all of the therapeutic benefit, but analyses presented here suggest that antipsychotic actions are not subject to a sharp "all-or-none" threshold but increase over a small dose range. This concept could provide a method for quantitative determination of individualized optimal doses.

Citing Articles

The incidence risk of gynecological cancer by antipsychotic use: a meta-analysis of 50,402 patients.

de Moraes F, Sudo R, Cavalcanti Souza M, Fernandes M, Dos Santos N BMC Cancer. 2024; 24(1):712.

PMID: 38858638 PMC: 11163728. DOI: 10.1186/s12885-024-12481-6.

Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.

Pieters T, TSas S, Vanhee S, Almeida A, Driege Y, Roels J J Exp Med. 2021; 218(10).

PMID: 34406363 PMC: 8377631. DOI: 10.1084/jem.20202280.

Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials.

Patton E, Zon L, Langenau D Nat Rev Drug Discov. 2021; 20(8):611-628.

PMID: 34117457 PMC: 9210578. DOI: 10.1038/s41573-021-00210-8.

Retracted: Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2.

Morita K, He S, Nowak R, Wang J, Zimmerman M, Fu C Cell. 2020; 181(3):702-715.e20.

PMID: 32315619 PMC: 7397863. DOI: 10.1016/j.cell.2020.03.051.

Binding of clozapine to the GABA receptor: clinical and structural insights.

Nair P, McKinnon R, Miners J, Bastiampillai T Mol Psychiatry. 2020; 25(9):1910-1919.

PMID: 32203158 DOI: 10.1038/s41380-020-0709-5.

References

Cohen B, Lipinski J, Waternaux C . A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology (Berl). 1989; 97(4):481-8. DOI: 10.1007/BF00439552. View

Bolden C, Cusack B, Richelson E . Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther. 1992; 260(2):576-80. View

Scholz E, Dichgans J . Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci. 1985; 235(1):60-4. DOI: 10.1007/BF00380972. View

Gefvert O, Lundberg T, Wieselgren I, Bergstrom M, Langstrom B, Wiesel F . D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol. 2001; 11(2):105-10. DOI: 10.1016/s0924-977x(00)00133-4. View

Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey J . Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol. 2006; 29(4):215-9. DOI: 10.1097/01.WNF.0000228176.98582.93. View

Potkin S, Shen Y, Zhou D, Pardes H, Shu L, Phelps B . Does a therapeutic window for plasma haloperidol exist?: Preliminary Chinese data. Psychopharmacol Bull. 1985; 21(1):59-61. View

McEvoy J, Hogarty G, Steingard S . Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991; 48(8):739-45. DOI: 10.1001/archpsyc.1991.01810320063009. View

Scatton B . Further evidence for the involvement of D2, but not D1 dopamine receptors in dopaminergic control of striatal cholinergic transmission. Life Sci. 1982; 31(25):2883-90. DOI: 10.1016/0024-3205(82)90679-8. View

Dickson R, Williams R, Dalby J . Dystonic reaction and relapse with clozapine discontinuation and risperidone intiation. Can J Psychiatry. 1994; 39(3):184. DOI: 10.1177/070674379403900318. View

10.

Friedman J, Goldstein S, Jacques C . Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol. 1998; 21(5):285-8. View

11.

Stoof J, Verheijden P, Leysen J . Stimulation of D2-receptors in rat nucleus accumbens slices inhibits dopamine and acetylcholine release but not cyclic AMP formation. Brain Res. 1987; 423(1-2):364-8. DOI: 10.1016/0006-8993(87)90864-x. View

12.

Sacchetti E, Panariello A, Regini C, Valsecchi P . Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. Schizophr Res. 2004; 69(2-3):325-31. DOI: 10.1016/s0920-9964(03)00225-1. View

13.

Mauri M, Steinhilber C, Marino R, Invernizzi E, Fiorentini A, Cerveri G . Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry. 2005; 20(1):55-60. DOI: 10.1016/j.eurpsy.2004.09.009. View

14.

Caligiuri M, Teulings H, Filoteo J, Song D, Lohr J . Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism. Hum Mov Sci. 2006; 25(4-5):510-22. DOI: 10.1016/j.humov.2006.02.004. View

15.

Kirch D, BIGELOW L, Korpi E, Wagner R, Zalcman S, Wyatt R . Serum haloperidol concentration and clinical response in schizophrenia. Schizophr Bull. 1988; 14(2):283-9. DOI: 10.1093/schbul/14.2.283. View

16.

Meisenzahl E, Dresel S, Frodl T, Schmitt G, Preuss U, Rossmuller B . D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J Psychopharmacol. 2001; 14(4):364-70. DOI: 10.1177/026988110001400405. View

17.

Shiovitz T, Welke T, Tigel P, Anand R, Hartman R, Sramek J . Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull. 1996; 22(4):591-5. DOI: 10.1093/schbul/22.4.591. View

18.

BIGELOW L, Kirch D, Braun T, Korpi E, Wagner R, Zalcman S . Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study. Psychopharmacol Bull. 1985; 21(1):66-8. View

19.

Garver D, Hirschowitz J, Glicksteen G, Kanter D, Mavroidis M . Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol. 1984; 4(3):133-7. View

20.

Chouinard G . Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res. 1991; 5(1):21-33. DOI: 10.1016/0920-9964(91)90050-2. View